financetom
Business
financetom
/
Business
/
Why Is JD.com Stock Shooting Upwards Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is JD.com Stock Shooting Upwards Wednesday?
Mar 6, 2024 3:58 AM

JD.com, Inc ( JD ) reported fourth-quarter fiscal 2023 revenue growth of 3.6% year-on-year to $43.1 billion, beating the consensus of $42.2 billion.

The Alibaba Group Holding Limited ( BABA ) rival’s adjusted net income per ADS of $0.75 beat the consensus of $0.63. The stock price climbed after the results.

JD Segment Performance: JD.com’s net product revenue climbed by 3.7% Y/Y to $34.7 billion. Net service revenues rose 3.0% Y/Y to $8.4 billion. JD Retail revenue climbed 3.4% Y/Y to $37.7 billion.

Margin: Adjusted operating margin remained firm at 2.5%. Adjusted operating margin of JD Retail was 2.6%, versus 3.0% Y/Y. 

JD.com ( JD ) generated $1.87 billion in free cash flow for the quarter and held $27.8 billion in cash and equivalents as of December 31, 2023.

Buyback and Dividend: The board approved a new buyback program of up to $3.0 billion worth of its shares (including ADSs) over the next 36 months through March 2027.

The board also approved an annual cash dividend for the year ended December 31, 2023, of $0.38 per ordinary share, or $0.76 per ADS, to holders of ordinary shares and holders of ADSs.

CFO Ian Su Shan said, “Our core home appliance and electronics categories continued to outperform the industry, and general merchandise category returned to a growth trajectory in the quarter.” 

Investors can gain exposure to JD.com ( JD ) via Invesco Golden Dragon China ETF ( PGJ ) and VanEck Retail ETF ( RTH ) .

Price Action: JD shares traded higher by 11.7% at $23.95 in the premarket session on the last check Wednesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
Jul 11, 2025
Milestone Pharmaceuticals Inc. ( MIST ) moved closer to potential FDA approval for its Cardamyst (etripamil) nasal spray, an investigational therapy for paroxysmal supraventricular tachycardia (PSVT), as the U.S. Food and Drug Administration (FDA) accepted the company’s response to prior issues. However, shares of Milestone Pharmaceuticals ( MIST ) plummeted over 36% on Friday following the pricing of a public...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
SuperBuzz Announces Shares for Debt Offering for up to $100,000
SuperBuzz Announces Shares for Debt Offering for up to $100,000
Jul 11, 2025
12:23 PM EDT, 07/11/2025 (MT Newswires) -- SuperBuzz (SPZ.V) on Friday said it plans to complete a shares for debt offering for up to $100,000. The company will issue 416,667 shares priced at $0.24 each. The offering is subject to the company obtaining all necessary corporate and regulatory approvals. The company's shares were last seen up $0.005 to $0.32 on...
Novartis loses bid to block US Entresto generic through 2026
Novartis loses bid to block US Entresto generic through 2026
Jul 11, 2025
July 11 (Reuters) - Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday. U.S. District Judge Richard Andrews rejected Novartis' argument that MSN's generic would infringe one of its patents and denied its request to block the generic from launching until after...
Copyright 2023-2026 - www.financetom.com All Rights Reserved